-
Bold Therapeutics Presents Late-Breaking Poster on BOLD-100’s Unique Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN) at AACR Annual Meeting 2025
VANCOUVER, BC, April 30, 2025 /PRNewswire/ — Bold Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering novel oncology treatments, today announced that its Sr. Director of Preclinical Development, Mark Bazett, PhD, is presenting a late-breaking poster on BOLD-100’s potent neuroprotective properties later today at the American Association for Cancer Research (AACR) Annual Meeting 2025.Session: Late-Breaking Research: Experimental
-
AllyGPO and BioCareSD: Tech-Forward Partners Deliver Unsurpassed Innovation to Community Oncology
Delivering greater value to independent oncology practices with technology-driven specialty drug management. ORLANDO, Fla., April 30, 2025 /PRNewswire/ — At the 2025 Community Oncology Alliance (COA) Annual Meeting, AllyGPO® group purchasing organization and BioCareSD® specialty distribution demonstrated how their partnership and strategic technology investments are setting a new standard for delivering innovation and value to
-
Ingenium Therapeutics Receives FDA Feedback Enabling Direct Phase 2 Trial for Gengleucel in MRD+ AML
SEOUL, South Korea, April 30, 2025 /PRNewswire/ — Ingenium Therapeutics, a clinical-stage biotechnology company advancing allogeneic natural killer (NK) cell therapies, today announced that it has received positive regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Pre-Investigational New Drug (Pre-IND) meeting. Ingenium has conducted multiple investigator-initiated trials in South Korea, enrolling
-
iStorage | Kanguru Unveils Their New Streamlined, On-Premise Edition to the KRMC Remote Management Platform
MILLIS, Mass., April 30, 2025 /PRNewswire/ — iStorage | Kanguru, a global leader in secure, hardware-encrypted data storage solutions, proudly announces the launch of their updated KRMC™ (Kanguru Remote Management Console) On-Premise Edition—an advanced, self-hosted solution designed to meet the high-security demands of government, defense, healthcare and other critical sectors. This latest edition introduces a
-
DCN Dx Announces Call for Poster Abstracts for Advanced Lateral Flow Conference 2025 – Premier Diagnostics Event Returns to La Jolla
Researchers invited to showcase studies at premier lateral flow diagnostics event LA JOLLA, Calif., April 30, 2025 /PRNewswire/ — The Advanced Lateral Flow Conference (ALFC) is now accepting applications for poster presentations at its 2025 event, taking place October 14-15, 2025, at the Hilton La Jolla Torrey Pines in La Jolla, California. ALFC is the global
-
Advanced Lateral Flow Conference 2025 Now Accepting Speaker Applications
Call for Experts to Share Practical Insights and Strategic Lessons at the Premier LFA Industry Event LA JOLLA, Calif., April 30, 2025 /PRNewswire/ — The Advanced Lateral Flow Conference (ALFC) is now accepting speaker applications for its 2025 program, taking place October 14-15, 2025, at the Hilton La Jolla Torrey Pines. ALFC is the leading global
-
AlphaRose Therapeutics Announces Acquisition of Alpha Anomeric SA, a French Company with Industry-Leading Oligonucleotide Technology
Acquisition positions AlphaRose as a leader in next generation Antisense Oligonucleotide Therapeutics with a novel proprietary oligonucleotide chemistry (abcDNA) platform invented at University of Bern, Switzerland Establishes a presence for AlphaRose in Europe, with Alpha Anomeric headquartered in Paris, France abcDNA Chemistry platform validated in ASO gapmer constructs, a core focus of AlphaRose Therapeutics’ programs
-
TheraLight Unveils New 360 Model Featuring Enhanced Technology and Optimized Wellness Benefits
LINDON, Utah, April 28, 2025 /PRNewswire/ — TheraLight, LLC, a pioneer in whole-body photobiomodulation therapy, proudly announces the launch of its latest innovation: the new TheraLight 360, a next-generation model designed to deliver enhanced performance, improved user experience, and expanded therapeutic benefits. The New TheraLight 360 Model Since launching the original TheraLight 360 model in
-
TheraLight Introduces the New TheraLight FIT: Advanced Full-Body Red Light Therapy Bed Now Engineered for 110V Power
LINDON, Utah, April 28, 2025 /PRNewswire/ — TheraLight, LLC, a leading innovator in photomedicine technology, announces the upcoming release of the TheraLight FIT, an advanced full-body red light therapy bed specifically engineered for standard 110V outlets and will succeed the original, introducing a series of carefully designed upgrades driven by years of clinical success, customer
-
Bold Therapeutics Announces Presentation of Late-Breaking Data on BOLD-100’s Unique Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN)
VANCOUVER, BC., April 28, 2025 /PRNewswire/ — Bold Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering novel oncology treatments, today announced that its Sr. Director of Preclinical Development, Mark Bazett, PhD, will be presenting a late-breaking poster on BOLD-100’s potent neuroprotective properties at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25–30,
